Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation

18-04-2024 | Hyperparathyroidism | Review

Familial states of primary hyperparathyroidism: an update

Authors: F. Cetani, E. Dinoi, L. Pierotti, E. Pardi

Published in: Journal of Endocrinological Investigation

Login to get access

Abstract

Background

Familial primary hyperparathyroidism (PHPT) includes syndromic and non-syndromic disorders. The former are characterized by the occurrence of PHPT in association with extra-parathyroid manifestations and includes multiple endocrine neoplasia (MEN) types 1, 2, and 4 syndromes, and hyperparathyroidism–jaw tumor (HPT–JT). The latter consists of familial hypocalciuric hypercalcemia (FHH) types 1, 2 and 3, neonatal severe primary hyperparathyroidism (NSHPT), and familial isolated primary hyperparathyroidism (FIHP). The familial forms of PHPT show different levels of PHPT penetrance, developing earlier and with multiglandular involvement compared to sporadic counterpart.
All these diseases exhibit Mendelian inheritance patterns, and for most of them, the genes responsible have been identified. DNA testing for predisposing mutations is helpful in index cases or in individuals with a high suspicion of the disease. Early recognition of hereditary disorders of PHPT is of great importance for the best clinical and surgical approach. Genetic testing is useful in routine clinical practice because it will also involve appropriate screening for extra-parathyroidal manifestations related to the syndrome as well as the identification of asymptomatic carriers of the mutation.

Purpose

The aim of the review is to discuss the current knowledge on the clinical and genetic profile of these disorders along with the importance of genetic testing in clinical practice.
Literature
1.
2.
Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A et al (2022) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30:e220174PubMed
3.
Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J et al (2024) Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review. J Clin Endocrinol Metab 1–12
4.
Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106(4):1163–1182PubMedCrossRef
5.
Marx SJ, Goltzman D (2019) Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. J Bone Min Res 34(1):22–37CrossRef
6.
Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T et al (2013) Mutations affecting G-protein subunit α 11 in hypercalcemia and hypocalcemia. N Engl J Med 368(26):2476–2486PubMedPubMedCentralCrossRef
7.
Nesbit MA, Hannan FM, Howles SA, Reed AAC, Cranston T, Thakker CE et al (2013) Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 45(1):93–97PubMedCrossRef
8.
9.
10.
Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M et al (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4):613–622PubMedCrossRef
11.
Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:1–15CrossRef
12.
Trump D, Farren B, Wooding C, Pang J, Besser G, Buchanan K et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 89:653–669CrossRef
13.
14.
Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S et al (2009) Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 24(8):1404–1410PubMedCrossRef
15.
Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab 100(4):1568–1577PubMedCrossRef
16.
Yavropoulou MP, Vlachou S, Tsoli M, Fostira F, Kaltsas G, Kassi E (2022) Management and long-term follow-up of hyperparathyroidism in multiple endocrine neoplasia type 1: single center experience. J Clin Med 11(7):1–11CrossRef
17.
18.
Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML (2007) Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 246(6):1075–1082PubMedCrossRef
19.
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S et al (2022) Evaluation and management of primary hyperparathyroidism : summary statement and guidelines from the fifth international workshop. J Bone Miner Res 37(12):2568–2585PubMed
20.
De Menezes Montenegro FL, Brescia MDEG, Lourenço DM, Arap SS, D’Alessandro AF, De Britto E Silva Filho G et al (2019) Could the less-than subtotal parathyroidectomy be an option for treating young patients with multiple endocrine neoplasia type 1-related hyperparathyroidism? Front Endocrinol (Lausanne) 10:1–10
21.
Choi HR, Choi SH, Choi SM, Kim JK, Lee CR, Kang SW et al (2020) Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism. Sci Rep 10(1):1–7
22.
Brandi M, Agarwal S, Perrier N, Lines K, Valk G, Thakker R (2021) Multiple endocrine neoplasia type 1: latest insights. Endocr Rev 42(2):133–170PubMedCrossRef
23.
Mai HD, Sanowski RA (1992) Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy. Gastrointest Endosc 38(6):706–708PubMedCrossRef
24.
Nastos C, Papaconstantinou D, Kofopoulos-Lymperis E, Peppa M, Pikoulis A, Lykoudis P et al (2021) Optimal extent of initial parathyroid resection in patients with multiple endocrine neoplasia syndrome type 1: a meta-analysis. Surg (United States) 169(2):302–310
25.
Bouriez D, Gronnier C, Haissaguerre M, Tabarin A, Najah H (2022) Less than subtotal parathyroidectomy for multiple endocrine neoplasia type 1 primary hyperparathyroidism: a systematic review and meta-analysis. World J Surg 46(11):2666–2675PubMedCrossRef
26.
Iacobone M, Carnaille B, Palazzo FF, Vriens M (2015) Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck’s Arch Surg 400(8):867–886CrossRef
27.
Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L et al (2024) French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophonede Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1. Ann Endocrinol (Paris) 85(1):2–19PubMedCrossRef
28.
Kluijfhout WP, Beninato T, Drake FT, Vriens MR, Gosnell J, Shen WT et al (2016) Unilateral clearance for primary hyperparathyroidism in selected patients with multiple endocrine neoplasia type 1. World J Surg 40(12):2964–2969PubMedPubMedCentralCrossRef
29.
Moyes VJ, Monson JP, Chew SL, Akker SA (2010) Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol 2010:10–13CrossRef
30.
Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99(10):3570–3579PubMedCrossRef
31.
Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A et al (2016) Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine 52(3):495–506PubMedCrossRef
32.
33.
Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S et al (2012) Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest 35(7):655–660PubMed
34.
Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S et al (2012) MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 167(2):157–164PubMedCrossRef
35.
Donegan D, Singh Ospina N, Rodriguez-Gutierrez R, Al-Hilli Z, Thompson GB, Clarke BL et al (2017) Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf) 86(2):199–206PubMedCrossRef
36.
37.
38.
Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H et al (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30(5):560–574PubMedCrossRef
39.
Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M et al (2021) Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome—an International Consensus Statement. Neuroendocrinology 111(7):609–630PubMedCrossRef
40.
Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101(2):266–273PubMedCrossRef
41.
Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P et al (2010) Risk factors and causes of death in men1 disease. A GTE (Groupe d’etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34(2):249–255
42.
Liu X, Chen B, Chen J, Su Z, Sun S (2023) The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. J Endocrinol Invest 46(7):1373–1384PubMedCrossRef
43.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al (2001) Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671PubMedCrossRef
44.
Cioppi F, Cianferotti L, Masi L, Giusti F, Brandi M (2017) The LARO-MEN1 study: a longitudinal clinical experience with octreotide long-acting release in patients with multiple endocrine neoplasia type 1 syndrome. Clin Cases Miner Bone Metab 14(2):123–130PubMedPubMedCentralCrossRef
45.
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V et al (2014) Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 80(6):850–855PubMedCrossRef
46.
Faggiano A, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B et al (2020) Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J Clin Endocrinol Metab 105(1):78–84CrossRef
47.
Frost M, Lines KE, Thakker RV (2019) Europe PMC Funders Group current and emerging therapies for pancreatic neuroendocrine tumours in patients with or without multiple endocrine neoplasia type 1. Nat Rev Endocrinol 14(4):216–227CrossRef
48.
Cohen-Cohen S, Brown DA, Himes BT, Wheeler LP, Ruff MW, Major BT et al (2020) Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience. J Neurosurg 134(4):1132–1138PubMedCrossRef
49.
De Laat JM, Pieterman CR, Van Den Broek MF, Twisk JW, Hermus AR, Dekkers OM et al (2014) Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab 99(9):3325–3333PubMedCrossRef
50.
Darling TN, Skarulis MC, Seth M, Spiegel AM, Turner M, Marx SJ (1997) Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133(7):853–857PubMedCrossRef
51.
Vidal A, Iglesias MJ, Fernández B, Fonseca E, Cordido F (2008) Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 22(7):835–838PubMedCrossRef
52.
Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT (2004) Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 89(11):5328–5336PubMedCrossRef
53.
Sakurai A, Matsumoto K, Ikeo Y, Nishio SI, Kakizawa T, Arakura F et al (2000) Frequency of facial angiofibromas in Japanese patients with multiple endocrine neoplasia type 1. Endocr J 47(5):569–573PubMedCrossRef
54.
Pierotti L, Pardi E, Dinoi E, Piaggi P, Borsari S, Della Valentina S et al (2023) Cutaneous lesions and other non-endocrine manifestations of multiple endocrine neoplasia type 1 syndrome. Front Endocrinol (Lausanne) 14(July):1–13
55.
Dreijerink KM, Goudet P, Burgess J, Valk G, Group IBC in MS (2014) Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med 371(6):583–584
56.
Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P (2021) Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol 17(4):207–224PubMedCrossRef
57.
58.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC et al (1997) Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 6(7):1169–1175PubMedCrossRef
59.
Chandrasekharappa SC, Guru SC, Manickam P, Emmanuel OS, Emmet-t-Buck FS, Collins M et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (80- ) 276:404–407
60.
Pardi E, Borsari S, Saponaro F, Bogazzi F, Urbani C, Mariotti S et al (2017) Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS One 12(10)
61.
Balogh K, Patócs A, Hunyady L, Rácz K (2010) Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol 326(1–2):80–84PubMedCrossRef
62.
63.
Agarwal SK, Impey S, McWeeney S, Scacheri PC, Collins FS, Goodman RH et al (2007) Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 9(2):101–107PubMedPubMedCentralCrossRef
64.
Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK et al (1989) Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 321(4):218–224PubMedCrossRef
65.
Mele C, Mencarelli M, Caputo M, Mai S, Pagano L, Aimaretti G et al (2020) Phenotypes associated with MEN1 syndrome: a focus on genotype-phenotype correlations. Front Endocrinol (Lausanne) 11(November):1–16
66.
Lips CJ, Dreijerink KM, Höppener JW (2012) Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics 67(Supplement):49–56PubMedPubMedCentralCrossRef
67.
Turner JJO, Christie PT, Pearce SHS, Turnpenny PD, Thakker RV (2010) Diagnostic challenges due to phenocopies: lessons from multiple endocrine neoplasia type1 (MEN1). Hum Mutat 31(1):1089–1101CrossRef
68.
Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94(5):1826–1834PubMedPubMedCentralCrossRef
69.
Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103(42):15558–15563PubMedPubMedCentralCrossRef
70.
71.
Molatore S, Kügler A, Irmler M, Wiedemann T, Neff F, Feuchtinger A et al (2018) Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma. Endocr Relat Cancer 25(2):145–162PubMedCrossRef
72.
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene p27 Kip1 is haplo-insufficient for tumour suppression. Nature 396(6707):177–180PubMedPubMedCentralCrossRef
73.
Bencivenga D, Stampone E, Aulitto A, Tramontano A, Barone C, Negri A et al (2021) A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function. Mol Oncol 15(4):915–941PubMedPubMedCentralCrossRef
74.
Singeisen H, Melanie Renzulli M, Pavlicek V, Probst P, Hauswirth F, Muller MK et al (2022) Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect 12(2):e220411
75.
Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto MR, Barcons S, Guirao X et al (2023) Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism. J Endocrinol Invest 46(4):829–840PubMedCrossRef
76.
Khairi S, Osborne J, Jacobs MF, Clines GT, Miller BS, Hughes DT et al (2020) Outcome of clinical genetic testing in patients with features suggestive for hereditary predisposition to PTH-mediated hypercalcemia. Horm Cancer 11(5–6):250–255PubMedPubMedCentralCrossRef
77.
Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A (2011) Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 96(4):1–6CrossRef
78.
Elston MS, Meyer-Rochow GY, Dray M, Swarbrick M, Conaglen JV (2015) Early onset primary hyperparathyroidism associated with a novel germline mutation in CDKN1B. Case Rep Endocrinol 2015:1–4CrossRef
79.
Borsari S, Pardi E, Pellegata NS, Lee M, Saponaro F, Torregrossa L et al (2016) Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine 55:386–397PubMedCrossRef
80.
Cusan M, Mungo G, Zompit MDM, Segatto I, Belletti B, Baldassarre G (2018) Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front Endocrinol (Lausanne) 9(Jul):1–10
81.
Lee M, Pellegata NS (2013) Multiple endocrine neoplasia syndromes associated with mutation of p27. J Endocrinol Invest 36(9):781–787PubMed
82.
Pardi E, Mariotti S, Pellegata NS, Benfini K, Borsari S, Saponaro F et al (2015) Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. Endocr Connect 4(1):1–8PubMedCrossRef
83.
Lavezzi E, Brunetti A, Smiroldo V, Nappo G, Pedicini V, Vitali E et al (2022) Case report: new CDKN1B mutation in multiple endocrine neoplasia type 4 and brief literature review on clinical management. Front Endocrinol (Lausanne) 13(March):1–7
84.
Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV (2019) Clinical features of multiple endocrine neoplasia type 4—novel pathogenic variant and review of published cases. J Clin Endocrinol Metab 104:3637–3646PubMedPubMedCentralCrossRef
85.
Sambugaro S, Di Ruvo M, Ambrosio MR, Pellegata NS, Bellio M, Guerra A et al (2015) Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region. Endocrine 49(1):58–64PubMedCrossRef
86.
Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, Uberti EC et al (2010) A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 31(11):1–11CrossRef
87.
88.
Borsari S, Pardi E, Pellegata NS, Lee M, Saponaro F, Torregrossa L et al (2017) Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine 55(2):386–397PubMedCrossRef
89.
Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9(3):e1003350PubMedPubMedCentralCrossRef
90.
Brock P, Bustamante Alvarez J, Mortazavi A, Roychowdhury S, Phay J, Khawaja RA et al (2020) Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. Fam Cancer 19(2):189–192PubMedCrossRef
91.
Bugalho MJ, Domingues R (2016) Uncommon association of cerebral meningioma, parathyroid adenoma and papillary thyroid carcinoma in a patient harbouring a rare germline variant in the CDKN1B gene. BMJ Case Rep 2016:bcr2015213934PubMedPubMedCentralCrossRef
92.
Georgitsi M, Raitila A, Karhu A, Van Der Luijt RB, Aalfs CM, Sane T et al (2007) Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 92(8):3321–3325PubMedCrossRef
93.
Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M et al (2012) Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol 166(3):551–560PubMedCrossRef
94.
Donis-keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2a and FMTC. Hum Mol Genet 2(7):851–856PubMedCrossRef
95.
Mathiesen JS, Effraimidis G, Rossing M, Rasmussen ÅK, Hoejberg L, Bastholt L et al (2020) Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol 2022(79):163–179
96.
Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F et al (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World J Surg 20(7):808–813PubMedCrossRef
97.
Holm M, Vestergaard P, Poulsen MM, Rasmussen ÅK, Feldt-Rasmussen U, Bay M et al (2023) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A in Denmark: a nationwide population-based retrospective study in Denmark 1930–2021. Cancers (Basel) 15(7):2125PubMedCrossRef
98.
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610PubMedPubMedCentralCrossRef
99.
Raue E, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A et al (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238(4):369–373PubMedCrossRef
100.
Larsen LV, Mirebeau-Prunier D, Imai T, Alvarez-Escola C, Hasse-Lazar K, Censi S et al (2020) Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocr Connect 9(6):489–497PubMedPubMedCentralCrossRef
101.
Figueiredo AA, Saramago A, Cavaco BM, Simões-Pereira J, Leite V (2023) Familial parathyroid tumours—comparison of clinical profiles between syndromes. J Endocrinol Invest 46(9):1799–1806PubMedCrossRef
102.
Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I et al (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 32(1):51–58PubMedCrossRef
103.
Machens A, Elwerr M, Lorenz K, Weber F, Dralle H (2020) 100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A. Endocrine 68(2):368–376PubMedCrossRef
104.
Herfarth KKF, Bartsch D, Doherty GM, Wells J, Lairmore TC, Kraimps JL et al (1996) Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120(6):966–974PubMedCrossRef
105.
Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43(7):663–667PubMedCrossRef
106.
Burnichon N, Cascoń A, Schiavi F, Morales NP, Comino-Méndez I, Abermil N et al (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18(10):2828–2837PubMedCrossRef
107.
Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L (2022) Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol 33:197–227PubMedCrossRef
108.
Roszko KL, Blouch E, Blake M, Powers JF, Tischler AS, Hodin R et al (2017) Case report of a prolactinoma in a patient with a novel MAX mutation and bilateral pheochromocytomas. J Endocr Soc 1(11):1401–1407PubMedPubMedCentralCrossRef
109.
Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papathomas TG, Van Nederveen FH et al (2016) Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis. J Clin Endocrinol Metab 101(2):453–460PubMedCrossRef
110.
Petignot S, Daly AF, Castermans E, Korpershoek E, Scagnol I, Beckers P et al (2020) Pancreatic neuroendocrine neoplasm associated with a familial MAX deletion. Horm Metab Res 52(11):784–787PubMedCrossRef
111.
Tora R, Welch J, Sun J, Agarwal SK, Bell DA, Merino M et al (2023) Phenotypic profiling and molecular mechanisms in hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 108(12):3165–3177PubMedPubMedCentralCrossRef
112.
Torresan F, Iacobone M (2019) Clinical features, treatment, and surveillance of hyperparathyroidism-jaw tumor syndrome: an up-to-date and review of the literature. Int J Endocrinol 2019:1761030PubMedPubMedCentralCrossRef
113.
Christakis I, Vu T, Chuang HH, Fellman B, Silva-Figueroa AM, Williams MD et al (2017) The diagnostic accuracy of neck ultrasound, 4D-computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur J Radiol 95:82–88PubMedCrossRef
114.
Iacobone M, Camozzi V, Mian C, Pennelli G, Pagetta C, Casal Ide E et al (2020) Long-term outcomes of parathyroidectomy in hyperparathyroidism-jaw tumor syndrome: analysis of five families with CDC73 mutations. World J Surg 44(2):508–516PubMedCrossRef
115.
Mehta A, Patel D, Rosenberg A, Boufraqech M, Ellis R, Nilubol N et al (2015) Hyperparathyroidism-jaw tumor syndrome: results of surgical management. Surgery 156(6):1315–1325CrossRef
116.
Sarquis MS, Silveira LG, Pimenta FJ, Dias EP, Teh BT, Friedman E et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 143(5):630–640PubMedCrossRef
117.
Cetani F, Marcocci C, Torregrossa L, Pardi E (2019) Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 26(7):R441–R464PubMedCrossRef
118.
Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S et al (2008) Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest 31:900–904PubMedPubMedCentralCrossRef
119.
Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M et al (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 91(8):2827–2832PubMedCrossRef
120.
Aldred MJ, Talacko AA, Savarirayan R, Murdolo V, Mills AE, Radden BG et al (2006) Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 101(2):212–218CrossRef
121.
Haven CJ, Wong FK, Van Dam EWCM, Van Der Luijt R, Van Asperen C, Jansen J et al (2000) A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 85(4):1449–1454PubMed
122.
Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE et al (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257(1):18–26PubMedCrossRef
123.
Iacobone M, Masi G, Barzon L, Porzionato A, MacChi V, Ciarleglio FA et al (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394(5):817–825PubMedCrossRef
124.
Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilsons J et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32(4):676–680PubMedCrossRef
125.
Newey PJ, Bowl MR, Cranston T, Thakker RV (2010) Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat 31(3):295–307PubMedCrossRef
126.
Cardoso L, Stevenson M, Thakker RV (2017) Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat 38(12):1621–1648PubMedPubMedCentralCrossRef
127.
Bricaire L, Odou MF, Cardot-Bauters C, Delemer B, North MO, Salenave S et al (2013) Frequent large germline HRPT2 deletions in a french national cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98(2):403–408CrossRef
128.
Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P et al (2013) CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect 2(4):186–195PubMedPubMedCentralCrossRef
129.
Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729PubMedCrossRef
130.
Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89(11):5583–5591PubMedCrossRef
131.
132.
Pontikides N, Karras S, Kaprara A, Anagnostis P, Mintziori G, Goulis DG et al (2014) Genetic basis of familial isolated hyperparathyroidism: a case series and a narrative review of the literature. J Bone Miner Metab 32(4):351–366PubMedCrossRef
133.
134.
Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89(1):96–102PubMedCrossRef
135.
136.
Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L et al (2006) Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 64(2):146–152PubMedCrossRef
137.
Van Der Tuin K, Tops CMJ, Adank MA, Cobben JM, Hamdy NAT, Jongmans MC et al (2017) CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. J Clin Endocrinol Metab 102(12):4534–4540PubMedCrossRef
138.
Guan B, Welch JM, Sapp JC, Ling H, Li Y, Johnston JJ et al (2016) GCM2-activating mutations in familial isolated hyperparathyroidism. Am J Hum Genet 99(5):1034–1044PubMedPubMedCentralCrossRef
139.
Yamada T, Tatsumi N, Anraku A, Suzuki H, Kamejima S, Uchiyama T et al (2019) Gcm2 regulates the maintenance of parathyroid cells in adult mice. PLoS ONE 14(1):1–15CrossRef
140.
Canaff L, Guarnieri V, Kim Y, Wong BYL, Nolin-Lapalme A, Cole DEC et al (2022) Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders. Eur J Endocrinol 186(3):351–366PubMedPubMedCentralCrossRef
141.
Guan B, Welch JM, Vemulapalli M, Li Y, Ling H, Kebebew E et al (2017) Ethnicity of patients with germline GCM2-activating variants and primary hyperparathyroidism. J Endocr Soc 1(5):488–499PubMedPubMedCentralCrossRef
142.
Szalat A, Shpitzen S, Pollack R, Mazeh H, Durst R, Meiner V (2023) GCM2 p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism. Front Endocrinol (Lausanne) 14:1254156
143.
144.
Cetani F, Pardi E, Aretini P, Saponaro F, Borsari S, Mazoni L et al (2020) Whole exome sequencing in familial isolated primary hyperparathyroidism. J Endocrinol Invest 43(2):231–245PubMedCrossRef
145.
Vincze S, Peters NV, Kuo CL, Brown TC, Korah R, Murtha TD et al (2022) GCM2 variants in familial and multiglandular primary hyperparathyroidism. J Clin Endocrinol Metab 107(5):E2021–E2026PubMedCrossRef
146.
El Lakis M, Nockel P, Gaitanidis A, Guan B, Agarwal S, Welch J et al (2018) Probability of positive genetic testing results in patients with family history of primary hyperparathyroidism. J Am Coll Surg 226(5):933–938PubMedPubMedCentralCrossRef
147.
148.
149.
150.
Hinnie J, Bell E, McKillop E, Gallacher S (2001) The prevalence of familial hypocalciuric hypercalcemia. Calcif Tissue Int 68(4):216–218PubMedCrossRef
151.
Kos CH, Karaplis AC, Bin PJ, Hediger MA, Goltzman D, Mohammad KS et al (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111(7):1021–1028PubMedPubMedCentralCrossRef
152.
Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L et al (2022) European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol 186(2):R33-63PubMedCrossRef
153.
Guarnieri V, Battista C, Muscarella LA, Bisceglia M, De Martino D, Baorda F et al (2012) CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol 35(6):411–422CrossRef
154.
Hannan FM, Nesbit MA, Zhang C, Cranston T, Curley AJ, Harding B et al (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet 21(12):2768–2778PubMedCrossRef
155.
Mouly C, Vargas-Poussou R, Lienhardt A, Silve C, Hureaux M, Magdelaine C et al (2020) Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: a multicentre study of 77 adult patients. Clin Endocrinol (Oxf) 93(3):248–260PubMedCrossRef
156.
Vargas-Poussou R, Mansour-Hendili L, Baron S, Bertocchio JP, Travers C, Simian C et al (2016) Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism : similarities and differences. J Clin Endocrinol Metab 101(5):2185–2195PubMedCrossRef
157.
Firek AF, Kao PC, Heath H (1991) Plasma intact parathyroid hormone (PTH) and PTH-related peptide in familial benign hypercalcemia: greater responsiveness to endogenous PTH than in primary hyperparathyroidism. J Clin Endocrinol Metab 72(3):541–546PubMedCrossRef
158.
159.
Jones AR, Hare MJL, Brown J, Yang J, Meyer C, Milat F et al (2020) Familial hypocalciuric hypercalcemia in pregnancy: diagnostic pitfalls. JBMR Plus 4(6):1–5CrossRef
160.
Dershem R, Gorvin CM, Metpally RPR, Krishnamurthy S, Smelser DT, Hannan FM et al (2020) Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: prevalence in a large healthcare population. Am J Hum Genet 106(6):734–747PubMedPubMedCentralCrossRef
161.
Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV (2018) Calcium-sensing receptor in physiology and in calcitropic and non-calcitropic diseases. Nat Rev Endocrinol 15(1):33–51PubMedPubMedCentralCrossRef
162.
Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM (2004) Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 351(4):362–369PubMedCrossRef
163.
Song L, Liu L, Miller RT, Yan SX, Jackson N, Holt SA et al (2017) Glucocorticoid-responsive lymphocytic parathyroiditis and hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor: a case report and literature review. Eur J Endocrinol 177(1):K1-6PubMedCrossRef
164.
Makita N, Ando T, Sato J, Manaka K, Mitani K, Kikuchi Y et al (2019) Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. JCI Insight 4(8):1–13CrossRef
165.
Makita N, Sato J, Manaka K, Akahane K, Ito T, Yamazaki H et al (2022) Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies. JCI Insight 7(20):1–15CrossRef
166.
Gorvin CM, Cranston T, Hannan FM, Rust N, Qureshi A, Nesbit MA et al (2016) A G-protein subunit-α11 loss-of-function mutation, Thr54Met, causes familial hypocalciuric hypercalcemia type 2 (FHH2). J Bone Miner Res 31(6):1200–1206PubMedCrossRef
167.
Gorvin CM, Hannan FM, Cranston T, Valta H, Makitie O, Schalin-Jantti C et al (2018) Cinacalcet rectifies hypercalcemia in a patient with familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss-of-function Gα11 mutation. J Bone Miner Res 33(1):32–41PubMedCrossRef
168.
Hannan FM, Howles SA, Rogers A, Cranston T, Gorvin CM, Babinsky VN et al (2015) Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects. Hum Mol Genet 24(18):5079–5092PubMedPubMedCentralCrossRef
169.
McMurtry CT, Schranck FW, Walkenhorst DA, Murphy WA, Kocher DB, Teitelbaum SL et al (1992) Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (hypocalciuric) hypercalcemia. Am J Med 93(3):247–258PubMedCrossRef
170.
Howles SA, Hannan FM, Babinsky VN, Rogers A, Gorvin CM, Rust N et al (2016) Cinacalcet for symptomatic hypercalcemia caused by AP2S1 mutations. N Engl J Med 374(14):1396–1398PubMedPubMedCentralCrossRef
171.
Fujisawa Y, Yamaguchi R, Satake E, Ohtaka K, Nakanishi T, Ozono K et al (2013) Identification of AP2S1 mutation and effects of low calcium formula in an infant with hypercalcemia and hypercalciuria. J Clin Endocrinol Metab 98(12):2022–2027CrossRef
172.
Hendy GN, Canaff L, Newfield RS, Tripto-Shkolnik L, Wong BYL, Lee BSP et al (2014) Codon Arg15 mutations of the AP2S1 gene: common occurrence in familial hypocalciuric hypercalcemia cases negative for calcium-sensing receptor (CASR) mutations. J Clin Endocrinol Metab 99(7):1311–1315CrossRef
173.
Hovden S, Rejnmark L, Ladefoged SA, Nissen PH (2017) AP2S1 and GNA11 mutations—not a common cause of familial hypocalciuric hypercalcemia. Eur J Endocrinol 176(2):177–185PubMedCrossRef
174.
Gorvin CM, Metpally R, Stokes VJ, Hannan FM, Krishnamurthy SB, Overton JD et al (2018) Large-scale exome datasets reveal a new class of adaptor-related protein complex 2 sigma subunit (AP2σ) mutations, located at the interface with the AP2 alpha subunit, that impair calcium-sensing receptor signalling. Hum Mol Genet 27(5):901–911PubMedPubMedCentralCrossRef
175.
Hannan FM, Stevenson M, Bayliss AL, Stokes VJ, Stewart M, Kooblall KG et al (2021) Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2. Hum Mol Genet 30(10):880–892PubMedPubMedCentralCrossRef
176.
Marx SJ, Sinaii N (2020) Neonatal severe hyperparathyroidism: novel insights from calcium, PTH, and the CASR gene. J Clin Endocrinol Metab 105(4):1061–1078PubMedCrossRef
177.
Pollak M, Chou YHW, Marx S, Steinmann B, Cole D, Brandi M et al (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. J Clin Invest 93:1108–1112PubMedPubMedCentralCrossRef
178.
Al-Shanafey S, Al-Hosaini R, Al-Ashwal A, Al-Rabeeah A (2010) Surgical management of severe neonatal hyperparathyroidism: one center’s experience. J Pediatr Surg 45(4):714–717PubMedCrossRef
179.
Hannan FM, Babinsky VN, Thakker RV (2016) Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol 57(3):R127–R142PubMedPubMedCentralCrossRef
180.
Fisher MM, Cabrera SM, Imel EA (2015) Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients. Endocrinol Diabetes Metab Case Rep 2015:150040PubMedPubMedCentral
181.
Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S et al (2004) Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 163(10):589–594PubMedCrossRef
182.
Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E (2012) Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 129(3):812–816CrossRef
183.
Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R et al (2006) Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21(10):1666–1671PubMedCrossRef
Metadata
Title
Familial states of primary hyperparathyroidism: an update
Authors
F. Cetani
E. Dinoi
L. Pierotti
E. Pardi
Publication date
18-04-2024
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-024-02366-7
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits